News

Validating microdialysis sampling protocols for...

Microdialysis validation for Argireline requires rigorous attention to probe parameters, calibration, sample handling, and tissue physiology. This review

Assessing the Impact of Blinding and Allocation...

Blinding and allocation concealment can dramatically skew reported injection site reactions in AOD-9604 trials. Learn how to spot bias and interpret ISR

Adaptive Platform Trials for AOD-9604 Dose-Finding

Adaptive platform trials can accelerate AOD-9604 dose-finding while maintaining statistical rigor. This article reviews design choices, simulation evidence

Optimizing Blinding Protocols in AOD-9604 vs GL...

Weight loss is a visible efficacy signal that can break blinding in AOD-9604 vs GLP-1 agonist trials. This article examines blinding failure mechanisms

Detecting Assay Interference in AOD-9604 ELISA ...

ELISA kits for AOD-9604 can overestimate peptide levels due to cross-reactivity with fragments and co-administered peptides. LC-MS offers higher

Blinding and Placebo Selection in Argireline Fa...

Argireline facial EMG studies often fail due to poor blinding. Learn how placebo selection and protocol design, informed by CJC-1295 trials, can prevent